Figure 1

Comparison of clinical and pharmacokinetic parameters of dasatinib in patients with and without a T315I mutation: (A) plasma concentration 2 h after dasatinib administration (C _2h ), (B) maximum plasma concentration after dasatinib administration (C _max ), and (C) area under the plasma concentration-time curve from 0 to 4 h (AUC _0-4h ). Boxes represent interquartile ranges (IQR) with the median represented by bold horizontal lines. The ends of the whiskers (vertical lines) represent the smallest and largest values that are not outliers.